RXi Pharmaceuticals

Biotech startup RXi Pharmaceuticals of Westborough announced Tuesday it was approved for listing on the NASDAQ Capital Market and began trading on the exchange.

RXi Pharmaceuticals of Westborough has signed a five-year lease for 7,581 square feet of office and laboratory space in Marlborough, according to a filing Friday with the U.S. Securities and Exchange Commission.

Westborough-based RXi Pharmaceuticals has signed an agreement with a British company to distribute RXi's clinical-stage dermal scarring drug in the European Union ahead of regulatory approval. RXi said in a statement that Ethicor Ltd., a London-based specialty pharmaceuticals company that distributes unlicensed medicines used for unmet clinical needs, now has the distribution rights to RXI-109 in the European Union with the potential to distribute the drug to other parts of the world before the product is registered in the countries covered by the agreement.

RXi Pharmaceuticals of Westborough, which is pursuing approval of a drug aimed at minimizing post-surgical scarring, saw a 61-percent year-over-year increase in revenue for the third quarter, although it posted another loss, the biotech startup reported today.

Westborough-based biotechnology startup RXi Pharmaceuticals saw positive progression in the second quarter ended June 30, narrowing its losses compared to last year while gaining revenue and improving its cash position.

Westborough-based RXi Pharmaceuticals Corp., a clinical-phase biotechnology company focusing on RNA-target technology, has filed an application for listing on The NASDAQ Capital Market.

Westborough-based RXi Pharmaceuticals said the first double-blind study of its anti-scarring treatment using healthy volunteers had positive results.

Biotech startup RXi Pharmaceuticals of Westborough, which is pushing ahead with clinical trials for its first product, reported a $14.4-million loss during the first quarter, but saw $100,000 in revenue, compared with no revenue during the first quarter of 2012.

RXi Pharmaceuticals of Westborough narrowed its losses in the third quarter and took in $57,000 in revenue...

Tucked away inside a small lab in Worcester, David Tabatadze has been working to create genetic constructs...